Relieves inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. ANDA 206370, held by Taro. Clocortolone Pivalate.
As of Nov 16, 2026, ANDA 206370 (Clocortolone Pivalate), held by Taro, was first approved by FDA on Apr 21, 2020, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 21, 2020 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Clocortolone Pivalate0.1% · cream;topical | Clocortolone Pivalate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters